Venture-Ready Technologies are some of the University of Rochester’s most promising inventions. We believe the technologies and innovations described below have significant commercial potential. Some of these items could fit nicely into a company’s existing intellectual property portfolio to enhance a product line or help launch a new one. Others represent platform technologies that could constitute the foundation of a new startup company. In either case, we invite you to peruse the following which will be updated periodically with new featured patents. If anything is of interest, please contact UR Ventures.
This invention describes a novel vaccine against type 1 diabetes.
A biomarker to save time and money in the treatment of arthritis.
A method to enhance the effects of deep brain stimulation.
A safe and effective therapy based on the bacterial AvrA peptide for the treatment of inflammatory bowel and celiac diseases.
A vaccine effective against all four strains of the Dengue virus.
A method to suppress premature stop codons in order to generate full-length mRNA using target-specific guide mRNAs.
A protein/peptide-based therapy for the prevention and treatment of obesity with desirable side effect profile.
A method of remyelinating axons using oligodendrocyte progenitor cells.
A novel method for treating and preventing dental diseases.
A novel diagnostic biomarker for quickly differentiating between severe sepsis and systematic inflammatory response syndrome (SIRS), allowing the proper treatment to begin sooner than with current methods.
A novel synthetic lung surfactant for the treatment of neonatal and acute respiratory distress syndromes.
Methods for obtaining specific and non-toxic inhibitors of Activation Induced Deaminase (AID) nuclear import that prevent the progression of follicular lymphoma (FL), once diagnosed.
A human Biliverdin Reductase (hBVR) based peptide therapy for the treatment of diabetes.
A novel method for treating and preventing fibrosis and fibrosis-related conditions using fibronectin binding proteins and polypeptides.
A novel therapy method for delivering localized anti-cancer responses without adverse body-wide side effects.
A novel therapy using light-activated chemokine receptors to direct specific lymphocytes to desired locations within a patient’s body.
A novel protocol to produce large quantities of nearly 100% homogenous heavy-labeled acyl-CoAs rapidly and inexpensively.
Small compounds that inhibit the uptake of amyloid-β into the brain.
A new cell therapy for treating damage to the central nervous system.
A new approach to target genes exclusively to type I alveolar epithelial cells’ nuclei.
A treatment for hyperammonemic Encephalopathy and Seizures.